Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12544467 | 0.95 | HRH3 (0.37) | LMNAATMTP53POLBPRMT5 | |
| SCHEMBL14142083 | 0.90 | DRD2 (0.38) | DRD2LMNAATMTP53POLB | |
| SCHEMBL10180230 | 0.88 | GPR119 (0.49) | GPR119 | |
| SCHEMBL10179519 | 0.88 | ATM (0.34) | DRD2LMNAATMTP53POLB | |
| SCHEMBL10179523 | 0.88 | PRMT5 (0.33) | DRD2LMNAATMTP53POLB | |
| SCHEMBL10187803 | 0.87 | FASN (0.36) | DRD2PRMT5FASNGPR119 | |
| SCHEMBL10180513 | 0.87 | FASN (0.36) | PRMT5FASNGPR119 | |
| SCHEMBL10181085 | 0.87 | CCR2 (0.38) | DRD2PRMT5FASNGPR119RORC | |
| SCHEMBL14142231 | 0.87 | ATM (0.36) | LMNAATMTP53POLBPRMT5 | |
| SCHEMBL10179444 | 0.87 | GPR119 (0.34) | LMNAATMTP53POLBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | DRD2 267/4885LMNA 3326/4885ATM 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.